Page last updated: 2024-11-02

pioglitazone and Bile Duct Obstruction, Intrahepatic

pioglitazone has been researched along with Bile Duct Obstruction, Intrahepatic in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class."1.31Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. ( Kram, MT; Lefkowitch, JH; May, LD; Rubin, DE, 2002)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
May, LD1
Lefkowitch, JH1
Kram, MT1
Rubin, DE1

Other Studies

2 other studies available for pioglitazone and Bile Duct Obstruction, Intrahepatic

ArticleYear
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
    Annals of internal medicine, 2002, Mar-19, Volume: 136, Issue:6

    Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ

2002
Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
    Annals of internal medicine, 2002, Mar-19, Volume: 136, Issue:6

    Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ

2002